ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

February 20, 2008 11:26 ET

ART Announces First Sale of SoftScan Optical Breast Imaging System

Toronto's Sunnybrook Health Sciences Centre chooses SoftScan® as the right fit for their expanding breast imaging programme

MONTREAL, CANADA--(Marketwire - Feb. 20, 2008) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce the first sale of its SoftScan® optical breast imaging system to the Sunnybrook Health Sciences Centre ('Sunnybrook") in Toronto, Canada. Sunnybrook is the first health centre to purchase a SoftScan imaging system since ART received regulatory approval from Health Canada for the commercialization of its optical breast imaging device.

Dr. Gregory Czarnota, Radiation Oncologist at Odette Cancer Centre, Sunnybrook Health Sciences Centre, and Scientist in Imaging Research at Sunnybrook Research Institute, is the principal investigator of a pilot study to determine the role for the SoftScan system in monitoring response to treatment of breast cancer, particularly neoadjuvant therapies. He works with Dr. Martin Yaffe, Senior Scientist in Imaging Research at Sunnybrook Research Institute, in advancing this programme. Dr. Czarnota commented: "We are very encouraged by the results obtained so far with the SoftScan system, which offers us an objective method of measuring treatment response to breast cancer. Medical oncologists such as myself want to quantify, to put a number on what's occurring. SoftScan enables them to do this because it can identify tumours by their metabolic signatures."

"We are proud to partner with Dr. Czarnota, Dr. Yaffe, and their team at Sunnybrook as they conduct ground-breaking research into breast cancer treatment monitoring," said Sebastien Gignac, ART's President and CEO. "The SoftScan imaging system's ability to provide highly-sensitive functional information on the evolution of cancer lesions allows ART to contribute to the development of personalized medicine and help maximize the efficacy of therapies for women with breast cancer", concluded Mr. Gignac.

About the SoftScan® system

The SoftScan ® optical breast imaging system has been designed first as a complementary diagnostic tool to mammography, with ultimate uses in the detection and treatment monitoring of breast cancer. Its non-invasive, painless approach uses time-domain optical imaging technology, which may allow clinicians to better locate and characterize breast tumors as benign or malignant and could provide faster assessment of therapeutic effectiveness. Unlike mammography whose use must be strictly limited, the SoftScan system emits no radiation and can be safely used as often as needed to monitor patients. The device was created and developed by ART Advanced Research Technologies Inc., and has obtained regulatory approvals for its commercialization in Canada and in Europe.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contact Information